FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 332:1457-1463 June 1, 1995 Number 22 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background We studied the effects of long-term treatment with interferon on histologic features of the liver and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis.

Methods Consecutive patients who met the inclusion criteria were enrolled in the study. The diagnosis of chronic non-A, non-B hepatitis was established on the basis of the liver-biopsy findings and an abnormal serum alanine aminotransferase value (more than 1.5 times the normal value) for at least one year. All patients were treated for 6 months with 3 million units of interferon alfa-2b given subcutaneously three times a week and were then randomly assigned to the same treatment for an additional 12 months (group 1), a regimen of 1 million units three times a week for 12 months (group 2), or no further treatment (group 3). Patients in group 3 who had elevated serum alanine aminotransferase concentrations for three consecutive months underwent the initial regimen once again. Follow-up continued for two years after the discontinuation of treatment. Histologic improvement was defined as a decrease of at least one point in the score for necroinflammatory activity (0, no activity; 1, mild; 2, moderate; or 3, severe) between the first liver biopsy and a biopsy performed at 18 months.

Results Of the 329 patients initially treated, 303 were randomized: 103 to group 1, 101 to group 2, and 99 to group 3. Of the 286 patients tested, 252 (88.1 percent) had antibodies to hepatitis C virus. In an intention-to-treat analysis, 46 of the patients in group 1 (44.7 percent) had normal serum alanine aminotransferase values at 18 months, as compared with 27 of the patients in group 2 (26.7 percent, P = 0.008) and 30 of those in group 3 (30.3 percent, P = 0.04). Between 19 and 42 months, 23 of the patients in group 1 (22.3 percent) continued to have normal serum alanine aminotransferase values (measured every 6 months), as compared with 10 of the patients in group 2 (9.9 percent, P = 0.02) and 8 of those in group 3 (8.1 percent, P = 0.005). Among the 176 patients with repeated liver biopsies at 18 months, more patients in group 1 had improved histologic-activity scores (69.6 percent) than in group 2 (47.6 percent, P = 0.02) or group 3 (38.6 percent, P<0.001).

Conclusions Among patients with chronic non-A, non-B hepatitis, a regimen of 3 million units of interferon alfa-2b given three times a week for 18 months produced better histologic findings and serum alanine aminotransferase values than regimens involving a lower dose or a shorter duration of treatment.

Source Information

From the Service d'Hépato-Gastroentérologie, Hôpital Antoine Béclère, Clamart (T.P., J.C.C.); the Service d'Anatomie Pathologique, Hôpital de Bicêtre, Bicêtre (P.B.); Centre National de la Recherche Scientifique, Unité de Recherche Associée 1484, Paris (T.P., P.B., P.M., M.S., J.M.C., M.V.); Institut Pasteur, Lyons (M.C.); Schering–Plough Laboratories, Levallois (C.L.); the Services d'Hépato-Gastroentérologie Hôpital Hotel Dieu, Lyons (C.T.); Hôpital du Haut Lévèque, Pessac (P.C.); Hôpital Régional de Toulouse, Toulouse (J.L.P.); and Hôpital Américain de Paris, Neuilly (M.V., J.M.C.) — all in France.

Address reprint requests to Dr. Poynard at the Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié Salpétrière, 47-83 Boulevard de l'Hôpital, 75651 Paris CEDEX 13, France.

Full Text of this Article

This article has been cited by other articles:

• Navaneethan, U., Kemmer, N., Neff, G. W. (2009). Review: Predicting the probable outcome of treatment in HCV patients. Therapeutic Advances in Gastroenterology 2: 287-302 [Abstract]  
• Camacho, A., Ng, B. (2006). Methylphenidate for {alpha}-interferon induced depression. J Psychopharmacol 20: 687-689 [Abstract]  
• Wang, C.-Q., Li, Y., Douglas, S. D., Wang, X., Metzger, D. S., Zhang, T., Ho, W.-Z. (2005). Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. Am. J. Pathol. 167: 1333-1340 [Abstract] [Full Text]  
• Li, Y., Zhang, T., Douglas, S. D., Lai, J.-P., Xiao, W.-D., Pleasure, D. E., Ho, W.-Z. (2003). Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. Am. J. Pathol. 163: 1167-1175 [Abstract] [Full Text]  
• Booth, J C L, O'Grady, J, Neuberger, J (2001). Clinical guidelines on the management of hepatitis C. Gut 49: I1-21 [Full Text]  
• DOO, E, HOOFNAGLE, J H (2000). Combination therapy of hepatitis B. Gut 46: 450-451 [Full Text]  
• Munoz, A E, Levi, D, Podesta, A, Gorin, J M., Gonzalez, J, Bartellini, M A, Munne, M S, Cabanne, A, Flichman, D, Terg, R (2000). Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. Gut 46: 427-431 [Abstract] [Full Text]  
• Baffis, V., Shrier, I., Sherker, A. H., Szilagyi, A. (1999). Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection. ANN INTERN MED 131: 696-701 [Abstract] [Full Text]  
• Vogt, M., Lang, T., Frosner, G., Klingler, C., Sendl, A. F., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., Hess, J. (1999). Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. NEJM 341: 866-870 [Abstract] [Full Text]  
• McCarthy, M, Wilkinson, M L (1999). Recent advances: Hepatology. BMJ 318: 1256-1259 [Full Text]  
• Kenny-Walsh, E., The Irish Hepatology Research Group, (1999). Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin. NEJM 340: 1228-1233 [Abstract] [Full Text]  
• McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., Albrecht, J. K., The Hepatitis Interventional Therapy Group, (1998). Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. NEJM 339: 1485-1492 [Abstract] [Full Text]  
• Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., Albrecht, J., The International Hepatitis Interventional Therapy, (1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. NEJM 339: 1493-1499 [Abstract] [Full Text]  
• Casato, M., Agnello, V., Pucillo, L. P., Knight, G. B., Leoni, M., Del Vecchio, S., Mazzilli, C., Antonelli, G., Bonomo, L. (1997). Predictors of Long-Term Response to High-Dose Interferon Therapy in Type II Cryoglobulinemia Associated With Hepatitis C Virus Infection. Blood 90: 3865-3873 [Abstract] [Full Text]  
• Rumi, M. G., Santagostino, E., Morfini, M., Gringeri, A., Tagariello, G., Chistolini, A., Pontisso, P., Tagger, A., Colombo, M., Mannucci, P.M., the Hepatitis Study Group of the Association of It, (1997). A Multicenter Controlled, Randomized, Open Trial of Interferon alpha 2b Treatment of Anti-Human Immunodeficiency Virus-Negative Hemophilic Patients With Chronic Hepatitis C. Blood 89: 3529-3533 [Abstract] [Full Text]  
• Hoofnagle, J. H., Di Bisceglie, A. M. (1997). The Treatment of Chronic Viral Hepatitis. NEJM 336: 347-356 [Full Text]  
• Seymour, C. A (1996). Controversies in Management: Screening asymptomatic people at high risk for hepatitis C. BMJ 312: 1347-1348 [Full Text]  
• Allison, M. C, Mills, P. R (1996). Controversies in Management: Screening asymptomatic people at high risk for hepatitis C: The case against. BMJ 312: 1349-1350 [Full Text]  
• Sorrell, M. F. (1996). A 47-Year-Old Man With Asymptomatic Hepatitis C Infection. JAMA 275: 1023-1029 [Abstract]  
• Gane, E. J., Portmann, B. C., Naoumov, N. V., Smith, H. M., Underhill, J. A., Donaldson, P. T., Maertens, G., Williams, R. (1996). Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. NEJM 334: 815-821 [Abstract] [Full Text]  
• Dusheiko, G M, Khakoo, S, Soni, P, Grellier, L (1996). Fortnightly Review: A rational approach to the management of hepatitis C infection. BMJ 312: 357-364 [Abstract] [Full Text]  
• McNair, A N B, Tibbs, C J, Williams, R (1995). Recent Advances: Hepatology. BMJ 311: 1351-1355 [Full Text]  
• (1995). ...AND TREATMENT WITH INTERFERON. JWatch General 1995: 4-4 [Full Text]  
• Terrault, N., Wright, T. (1995). Interferon and Hepatitis C. NEJM 332: 1509-1511 [Full Text]